Targeting ion channels for cancer therapy by repurposing the approved drugs

Biochimica et Biophysica Acta - Biomembranes

Volumn 1848, Issue 10, 2015, Pages 2747-2755

  Kale, Vijay Pralhad ^a   Amin, Shantu G ^a   Pandey, Manoj K ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Ca++ channels; Cancer; Drug repurpose; Ion channels; K+ channels

Indexed keywords

AMLODIPINE; ASTEMIZOLE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; CHLORIDE CHANNEL; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; EPITHELIAL SODIUM CHANNEL; GLIBENCLAMIDE; IFOSFAMIDE; IMIPRAMINE; INWARDLY RECTIFYING POTASSIUM CHANNEL; ION CHANNEL; MEMANTINE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; QUINIDINE; RETIGABINE; RILUZOLE; TEMOZOLOMIDE; UNINDEXED DRUG; VERAPAMIL; VERNAKALANT; VINCRISTINE; VINDESINE; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

ARTICLE; BREAST CANCER; CANCER CELL LINE; CELL CYCLE ARREST; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG REPOSITIONING; DRUG RESPONSE; DRUG TARGETING; GLIOMA; HUMAN; LUNG CANCER; MELANOMA; MENINGIOMA; NEOPLASM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STOMACH CANCER; BIOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; COMPUTATIONAL BIOLOGY; DRUG REPOSITIONING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS;

EID: 84941260865     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2015.03.034     Document Type: Review

References (171)

1. American Cancer Society Cancer Facts & Figures 2014 American Cancer Society Atlanta
2. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
3. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
4. N. Prevarskaya, R. Skryma, and Y. Shuba Ion channels and the hallmarks of cancer Trends Mol. Med. 16 2010 107 121
5. P. Hainaut, and A. Plymoth Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy Curr. Opin. Oncol. 25 2013 50 51
6. + channels in human T lymphocytes: a role in mitogenesis? Nature 307 1984 465 468
7. L.A. Pardo, D. del Camino, A. Sanchez, F. Alves, A. Bruggemann, S. Beckh, and W. Stuhmer Oncogenic potential of EAG K(+) channels EMBO J. 18 1999 5540 5547
8. S. Pillozzi, M. Masselli, E. De Lorenzo, B. Accordi, E. Cilia, O. Crociani, A. Amedei, M. Veltroni, M. D'Amico, G. Basso, A. Becchetti, D. Campana, and A. Arcangeli Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers Blood 117 2011 902 914
9. D. Gomez-Varela, E. Zwick-Wallasch, H. Knotgen, A. Sanchez, T. Hettmann, D. Ossipov, R. Weseloh, C. Contreras-Jurado, M. Rothe, W. Stuhmer, and L.A. Pardo Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity Cancer Res. 67 2007 7343 7349
10. F. Hartung, W. Stuhmer, and L.A. Pardo Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody Mol. Cancer 10 2011
11. S.P. Fraser, and L.A. Pardo Ion channels: functional expression and therapeutic potential in cancer. Colloquium on ion channels and cancer EMBO Rep. 9 2008 512 515
12. K.M. Stroka, H.Y. Jiang, S.H. Chen, Z.Q. Tong, D. Wirtz, S.X. Sun, and K. Konstantopoulos Water permeation drives tumor cell migration in confined microenvironments Cell 157 2014 611 623
13. T.T. Ashburn, and K.B. Thor Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 3 2004 673 683
14. G.X. Jin, and S.T.C. Wong Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines Drug Discov. Today 19 2014 637 644
15. N.S. Jahchan, J.T. Dudley, P.K. Mazur, N. Flores, D. Yang, A. Palmerton, A.F. Zmoos, D. Vaka, K.Q.T. Tran, M. Zhou, K. Krasinska, J.W. Riess, J.W. Neal, P. Khatri, K.S. Park, A.J. Butte, and J. Sage A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors Cancer Discov. 3 2013 1364 1377
16. I. Amelio, M. Gostev, R.A. Knight, A.E. Willis, G. Melino, and A.V. Antonov DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information Cell. Death Dis. 5 2014 e1051
17. P. Pantziarka, G. Bouche, L. Meheus, V. Sukhatme, V.P. Sukhatme, and P. Vikas The Repurposing Drugs in Oncology (ReDO) project Ecancermedicalscience 8 2014 442
18. R. Huang, N. Southall, Y. Wang, A. Yasgar, P. Shinn, A. Jadhav, D.T. Nguyen, and C.P. Austin The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci. Transl. Med. 3 2011 (80ps16)
19. L.A. Pardo, and W. Stuhmer The roles of K(+) channels in cancer Nat. Rev. Cancer 14 2014 39 48
20. + channels in human lymphocyte-T - a role in mitogenesis Nature 307 1984 465 468
21. L.A. Pardo, C. Contreras-Jurado, M. Zientkowska, F. Alves, and W. Stuhmer Role of voltage-gated potassium channels in cancer J. Membr. Biol. 205 2005 115 124
22. B. Hemmerlein, R.M. Weseloh, F. Mello de Queiroz, H. Knotgen, A. Sanchez, M.E. Rubio, S. Martin, T. Schliephacke, M. Jenke, R. Heinz Joachim, W. Stuhmer, and L.A. Pardo Overexpression of Eag1 potassium channels in clinical tumours Mol. Cancer 5 2006 41
23. H. Ouadid-Ahidouch, M. Roudbaraki, P. Delcourt, A. Ahidouch, N. Joury, and N. Prevarskaya Functional and molecular identification of intermediate-conductance Ca(2 +)-activated K(+) channels in breast cancer cells: association with cell cycle progression Am. J. Physiol. Cell Physiol. 287 2004 C125 C134
24. + channel, a regulator of tumor cell apoptosis and proliferation Cancer Res. 62 2002 4843 4848
25. A.N. Mamelak, S. Rosenfeld, R. Bucholz, A. Raubitschek, L.B. Nabors, J.B. Fiveash, S. Shen, M.B. Khazaeli, D. Colcher, A. Liu, M. Osman, B. Guthrie, S. Schade-Bijur, D.M. Hablitz, V.L. Alvarez, and M.A. Gonda Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma J. Clin. Oncol. 24 2006 3644 3650
26. B.K. Stringer, A.G. Cooper, and S.B. Shepard Overexpression of the G-protein inwardly rectifying potassium channel 1 (GIRK1) in primary breast carcinomas correlates with axillary lymph node metastasis Cancer Res. 61 2001 582 588
27. H.K. Plummer III, M.S. Dhar, M. Cekanova, and H.M. Schuller Expression of G-protein inwardly rectifying potassium channels (GIRKs) in lung cancer cell lines BMC Cancer 5 2005 104
28. H.K. Plummer III, Q. Yu, Y. Cakir, and H.M. Schuller Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines BMC Cancer 4 2004 93
29. + current that regulates progression through early G1 phase of the cell cycle in MCF-7 human breast cancer cells J. Membr. Biol. 171 1999 35 46
30. I. Voloshyna, A. Besana, M. Castillo, T. Matos, I.B. Weinstein, M. Mansukhani, R.B. Robinson, C. Cordon-Cardo, and S.J. Feinmark TREK-1 is a novel molecular target in prostate cancer Cancer Res. 68 2008 1197 1203
31. D. Mu, L.Y. Chen, X.P. Zhang, L.H. See, C.M. Koch, C. Yen, J.J. Tong, L. Spiegel, K.C.Q. Nguyen, A. Servoss, Y. Peng, L. Pei, J.R. Marks, S. Lowe, T. Hoey, L.Y. Jan, W.R. McCombie, M.H. Wigler, and S. Powers Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene Cancer Cell 3 2003 297 302
32. + channel-mediated tumor cell proliferation and apoptosis Apoptosis 12 2007 1837 1846
33. S.G. Meuth, A.M. Herrmann, C.W. Ip, T. Kanyshkova, S. Bittner, A. Weishaupt, T. Budde, and H. Wiendl The two-pore domain potassium channel TASK3 functionally impacts glioma cell death J. Neuro-Oncol. 87 2008 263 270
34. B.R. Downie, A. Sanchez, H. Knotgen, C. Contreras-Jurado, M. Gymnopoulos, C. Weber, W. Stuhmer, and L.A. Pardo Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors J. Biol. Chem. 283 2008 36234 36240
35. + channels in human mesenteric artery - a single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ Circ. Res. 87 2000 496 503
36. J.W. Hu, X.P. Yuan, M.K. Ko, D.L. Yin, M.R. Sacapano, X. Wang, B.M. Konda, A. Espinoza, K. Prosolovich, J.M. Ong, D. Irvin, and K.L. Black Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model Mol. Cancer 6 2007
37. + channels inhibits proliferation of human endothelial cells induced by basic fibroblast growth factor J. Vasc. Res. 35 1998 363 371
38. E. Lastraioli, L. Guasti, O. Crociani, S. Polvani, G. Hofmann, H. Witchel, L. Bencini, M. Calistri, L. Messerini, M. Scatizzi, R. Moretti, E. Wanke, M. Olivotto, G. Mugnai, and A. Arcangeli herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells Cancer Res. 64 2004 606 611
39. M.B. McFerrin, and H. Sontheimer A role for ion channels in glioma cell invasion Neuron Glia Biol. 2 2006 39 49
40. M. Potier, V. Joulin, S. Roger, P. Besson, M.L. Jourdan, J.Y. LeGuennec, P. Bougnoux, and C. Vandier Identification of SK3 channel as a new mediator of breast cancer cell migration Mol. Cancer Ther. 5 2006 2946 2953
41. A. Schwab, A. Wulf, C. Schulz, W. Kessler, V. Nechyporuk-Zloy, M. Romer, J. Reinhardt, D. Weinhold, P. Dieterich, C. Stock, and S.C. Hebert Subcellular distribution of calcium-sensitive potassium channels (IK1) in migrating cells J. Cell. Physiol. 206 2006 86 94
42. W. Kessler, T. Budde, M. Gekle, A. Fabian, and A. Schwab Activation of cell migration with fibroblast growth factor-2 requires calcium-sensitive potassium channels Pflugers Arch. - Eur. J. Physiol. 456 2008 813 823
43. W.F. Wonderlin, K.A. Woodfork, and J.S. Strobl Changes in membrane-potential during the progression of Mcf-7 human mammary-tumor cells through the cell-cycle J. Cell. Physiol. 165 1995 177 185
44. S.Y. Wang, Z. Melkoumian, K.A. Woodfork, C. Cather, A.G. Davidson, W.F. Wonderlin, and J.S. Strobl Evidence for an early G1 ionic event necessary for cell cycle progression and survival in the MCF-7 human breast carcinoma cell line J. Cell. Physiol. 176 1998 456 464
45. + channel in mouse early embryos Nature 365 1993 560 562
46. X. Huang, and L.Y. Jan Targeting potassium channels in cancer J. Cell Biol. 206 2014 151 162
47. J.S. Strobl, W.F. Wonderlin, and D.C. Flynn Mitogenic signal transduction in human breast cancer cells Gen. Pharmacol. 26 1995 1643 1649
48. K.A. Woodfork, W.F. Wonderlin, V.A. Peterson, and J.S. Strobl Inhibition of Atp-sensitive potassium channels causes reversible cell-cycle arrest of human breast-cancer cells in tissue-culture J. Cell. Physiol. 162 1995 163 171
49. D. Urrego, A.P. Tomczak, F. Zahed, W. Stuhmer, and L.A. Pardo Potassium channels in cell cycle and cell proliferation Philos. Trans. R. Soc. Lond. B Biol. Sci. 369 2014 20130094
50. R. Meyer, R. Schonherr, O. Gavrilova-Ruch, W. Wohlrab, and S.H. Heinemann Identification of ether a go-go and calcium-activated potassium channels in human melanoma cells J. Membr. Biol. 171 1999 107 115
51. + channels in neoplastic hematopoietic cells J. Biol. Chem. 277 2002 18528 18534
52. F.M. de Queiroz, G. Suarez-Kurtz, W. Stuhmer, and L.A. Pardo Ether a go-go potassium channel expression in soft tissue sarcoma patients Mol. Cancer 5 2006
53. L.M.B. Farias, D.B. Ocana, L. Diaz, F. Larrea, E. Avila-Chavez, A. Cadena, L.M. Hinojosa, G. Lara, L.A. Villanueva, C. Vargas, E. Hernandez-Gallegos, I. Camacho-Arroyo, A. Duenas-Gonzalez, E. Perez-Cardenas, L.A. Pardo, A. Morales, L. Taja-Chayeb, J. Escamilla, C. Sanchez-Pena, and J. Camacho Ether a go-go potassium channels as human cervical cancer markers Cancer Res. 64 2004 6996 7001
54. S. Patt, K. Preussat, C. Beetz, R. Kraft, M. Schrey, R. Kalff, K. Schonherr, and S.H. Heinemann Expression of ether a go-go potassium channels in human gliomas Neurosci. Lett. 368 2004 249 253
55. A. Cherubini, G.L. Taddei, O. Crociani, M. Paglierani, A.M. Buccoliero, L. Fontana, I. Noci, P. Borri, E. Borrani, M. Giachi, A. Becchetti, B. Rosati, E. Wanke, M. Olivotto, and A. Arcangeli HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium Br. J. Cancer 83 2000 1722 1729
56. M.D. Benson, Q.J. Li, K. Kieckhafer, D. Dudek, M.R. Whorton, R.K. Sunahara, J.A. Iniguez-Lluhi, and J.R. Martens SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5 Proc. Natl. Acad. Sci. U. S. A. 104 2007 1805 1810
57. L.D. Plant, L. Zuniga, S. Olikara, and S.A.N. Goldstein One sumo is sufficient to silence the dimeric background potassium channel K2P1 Biophys. J. 107 23 2010 10743 10748
58. F. Lang, and E. Shumilina Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1 FASEB J. 27 2013 3 12
59. S.A. Norring, A.R. Ednie, T.A. Schwetz, D.P. Du, H. Yang, and E.S. Bennett Channel sialic acids limit hERG channel activity during the ventricular action potential FASEB J. 27 2013 622 631
60. R. Khanna, M.P. Myers, M. Laine, and D.M. Papazian Glycosylation increases potassium channel stability and surface expression in mammalian cells J. Biol. Chem. 276 2001 34028 34034
61. Q.M. Gong, C.L. Anderson, C.T. January, and Z.F. Zhou Role of glycosylation in cell surface expression and stability of HERG potassium channels Am. J. Physiol. Heart Circ. 283 2002 H77 H84
62. M.J. Shipston Ion channel regulation by protein palmitoylation J. Biol. Chem. 286 2011 8709 8716
63. X. Huang, A.M. Dubuc, R. Hashizume, J. Berg, Y. He, J. Wang, C. Chiang, M.K. Cooper, P.A. Northcott, M.D. Taylor, M.J. Barnes, T. Tihan, J. Chen, C.S. Hackett, W.A. Weiss, C.D. James, D.H. Rowitch, M.A. Shuman, Y.N. Jan, and L.Y. Jan Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics Genes Dev. 26 2012 1780 1796
64. J.J. Babcock, and M. Li hERG channel function: beyond long QT Acta Pharmacol. Sin. 34 2013 329 335
65. H.E. Lebovitz, and M.N. Feinglos Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness Diabetes Care 1 1978 189 198
66. J.V. Talano, and D. Feerst Verapamil. A new class of antiarrhythmic agents with a variety of beneficial cardiovascular effects Arch. Intern. Med. 140 1980 314 315
67. + channel opener for the treatment of epilepsy Epilepsia 53 2012 412 424
68. P. Proks, H. de Wet, and F.M. Ashcroft Molecular mechanism of sulphonylurea block of K-ATP channels carrying mutations that impair ATP inhibition and cause neonatal diabetes Diabetes 62 2013 3909 3919
69. S. Zhang, Z. Zhou, Q. Gong, J.C. Makielski, and C.T. January Mechanism of block and identification of the verapamil binding domain to HERG potassium channels Circ. Res. 84 1999 989 998
70. + channels and endoplasmic reticulum stress Int. J. Oncol. 41 2012 465 475
71. M. Nunez, V. Medina, G. Cricco, M. Croci, C. Cocca, E. Rivera, R. Bergoc, and G. Martin Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231 BMC Pharmacol. Toxicol. 14 2013
72. L. Payen, L. Delugin, A. Courtois, Y. Trinquart, A. Guillouzo, and O. Fardel The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells Br. J. Pharmacol. 132 2001 778 784
73. X. Qian, J. Li, J.H. Ding, Z.Y. Wang, L. Duan, and G. Hu Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH(2)-terminal kinase pathway in human gastric cancer cell tine MGC-803 Biochem. Pharmacol. 76 2008 1705 1715
74. + channel gating Mol. Pharmacol. 59 2001 1376 1387
75. H. Ikeda, G. Nakano, K. Nagashima, K. Sakamoto, N. Harasawa, T. Kitamura, T. Nakamura, and Y. Nagamachi Verapamil enhancement of antitumor effect of cis-diamminedichloroplatinum(II) in nude mouse-grown human neuroblastoma Cancer Res. 47 1987 231 234
76. W.F. Schmidt, K.R. Huber, R.S. Ettinger, and R.W. Neuberg Antiproliferative effect of verapamil alone on brain tumor cells in vitro Cancer Res. 48 1988 3617 3621
77. + channels as new regulators of non-small cell lung cancer cell proliferation and migration Int. J. Oncol. 44 2014 838 848
78. + channels by imipramine and astemizole J. Gen. Physiol. 124 2004 301 317
79. J. Garcia-Quiroz, and J. Camacho Astemizole: an old anti-histamine as a new promising anti-cancer drug Anti Cancer Agents Med. 11 2011 307 314
80. M.D. Chavez-Lopez, E. Hernandez-Gallegos, A.Y. Vazquez-Sanchez, P. Gariglio, and J. Camacho Antiproliferative and proapoptotic effects of astemizole on cervical cancer cells Int. J. Gynecol. Cancer 24 2014 824 828
81. + current: an external open channel blocker preventing fast inactivation Biophys. J. 75 1998 2845 2857
82. O. Gavrilova-Ruch, K. Schonherr, G. Gessner, R. Schonherr, T. Klapperstuck, W. Wohlrab, and S.H. Heinemann Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells J. Membr. Biol. 188 2002 137 149
83. V. Asher, A. Warren, R. Shaw, H. Sowter, A. Bali, and R. Khan The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line Cancer Cell Int. 11 2011
84. Y.F. Chen, Y.T. Chen, W.T. Chiu, and M.R. Shen Remodeling of calcium signaling in tumor progression J. Biomed. Sci. 20 2013
85. A. Panner, L.L. Cribbs, G.M. Zainelli, T.C. Origitano, S. Singh, and R.D. Wurster Variation of T-type calcium channel protein expression affects cell division of cultured tumor cells Cell Calcium 37 2005 105 119
86. T. Capiod, Y. Shuba, R. Skryma, and N. Prevarskaya Calcium signalling and cancer cell growth Subcell. Biochem. 45 2007 405 427
87. M. Li, and Z.G. Xiong Ion channels as targets for cancer therapy Int. J. Physiol. Pathophysiol. Pharmacol. 3 2011 156 166
88. C.R. Kahl, and A.R. Means Regulation of cell cycle progression by calcium/calmodulin-dependent pathways Endocr. Rev. 24 2003 719 736
89. 2 + currents in rat aortic smooth muscle cells in primary culture Circ. Res. 79 1996 14 19
90. A. Panner, and R.D. Wurster T-type calcium channels and tumor proliferation Cell Calcium 40 2006 253 259
91. I. Latour, D.F. Louw, A.M. Beedle, J. Hamid, G.R. Sutherland, and G.W. Zamponi Expression of T-type calcium channel splice variants in human glioma Glia 48 2004 112 119
92. S. Barnes, and L.W. Haynes Low-voltage-activated calcium channels in human retinoblastoma cells Brain Res. 598 1992 19 22
93. 2 + channel expression in human esophageal carcinomas: a functional role in proliferation Cell Calcium 43 2008 49 58
94. M. Toyota, C. Ho, M. Ohe-Toyota, S.B. Baylin, and J.P. Issa Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors Cancer Res. 59 1999 4535 4541
95. 2 + entry in cancer cells Cell Calcium 36 2004 489 497
96. F. Gackiere, G. Bidaux, P. Delcourt, F. Van Coppenolle, M. Katsogiannou, E. Dewailly, A. Bavencoffe, M.T. Van Chuoi-Mariot, B. Mauroy, N. Prevarskaya, and P. Mariot CaV3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells J. Biol. Chem. 283 2008 10162 10173
97. J.B. Huang, A.L. Kindzelskii, A.J. Clark, and H.R. Petty Identification of channels promoting calcium spikes and waves in HT1080 tumor cells: their apparent roles in cell motility and invasion Cancer Res. 64 2004 2482 2489
98. 2 + Life Sci. 82 2008 764 771
99. 2 + channel blocker, in human epidermoid carcinoma A431 cells Biochem. Pharmacol. 73 2007 943 953
100. T. Ono, N. Liu, H. Kusano, F. Nogaki, T. Makino, E. Muso, and S. Sasayama Broad antiproliferative effects of benidipine on cultured human mesangial cells in cell cycle phases Am. J. Nephrol. 22 2002 581 586
101. 2 + levels in human lung adenocarcinoma A549 cells Bioorg. Med. Chem. Lett. 22 2012 7123 7126
102. L. Helson Calcium channel blocker enhancement of anticancer drug cytotoxicity - a review Cancer Drug Deliv. 1 1984 353 361
103. C. Pauli-Magnus, O. von Richter, O. Burk, A. Ziegler, T. Mettang, M. Eichelbaum, and M.F. Fromm Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein J. Pharmacol. Exp. Ther. 293 2000 376 382
104. R.P. Mason Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J. Am. Coll. Cardiol. 34 1999 1857 1866
105. R. SoRelle Withdrawal of Posicor from market Circulation 98 1998 831 832
106. P.H. Bui, A. Quesada, A. Handforth, and O. Hankinson The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil Drug Metab. Dispos. 36 2008 1291 1299
107. 2 + channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms Mol. Pharmacol. 62 2002 210 219
108. S.T. Keir, L. Gray, and H.S. Friedman Abstract LB-76: mibefradil, a novel therapy for glioblastoma: an interlaced therapy approach Cancer Res. 72 2012 (LB-76)
109. S. Kondo, D. Yin, T. Morimura, H. Kubo, S. Nakatsu, and J. Takeuchi Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells Br. J. Cancer 71 1995 282 289
110. J.A. Largent, L. Bernstein, P.L. Horn-Ross, S.F. Marshall, S. Neuhausen, P. Reynolds, G. Ursin, J.A. Zell, A. Ziogas, and H. Anton-Culver Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort Cancer Causes Control 21 2010 1615 1624
111. C.R. Meier, L.E. Derby, S.S. Jick, and H. Jick Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer Arch. Intern. Med. 160 2000 349 353
112. C.I. Li, J.R. Daling, M.T.C. Tang, K.L. Haugen, P.L. Porter, and K.E. Malone Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years JAMA Intern. Med. 173 2013 1629 1637
113. J.S. Grundy, and R.T. Foster The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties Clin. Pharmacokinet. 30 1996 28 51
114. J.M. Taylor, and R.U. Simpson Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse Cancer Res. 52 1992 2413 2418
115. R.L. Jensen, and R.D. Wurster Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice Surg. Neurol. 55 2001 275 283
116. D. Belpomme, S. Gauthier, E. Pujade-Lauraine, T. Facchini, M.J. Goudier, I. Krakowski, G. Netter-Pinon, M. Frenay, C. Gousset, F.N. Marie, M. Benmiloud, and F. Sturtz Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma Ann. Oncol. 11 2000 1471 1476
117. M.J. Millward, B.M. Cantwell, N.C. Munro, A. Robinson, P.A. Corris, and A.L. Harris Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study Br. J. Cancer 67 1993 1031 1035
118. 2 + channel blockers on human epidermoid carcinoma A431 cells Eur. J. Pharmacol. 472 2003 23 31
119. W.S. Dalton, J.J. Crowley, S.S. Salmon, T.M. Grogan, L.R. Laufman, G.R. Weiss, and J.D. Bonnet A phase-III randomized study of oral verapamil as a chemosensitizer to reverse drug-resistance in patients with refractory myeloma - a Southwest-Oncology-Group study Cancer 75 1995 815 820
120. B.A. Jull, H.K. Plummer III, and H.M. Schuller Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells J. Cancer Res. Clin. Oncol. 127 2001 707 717
121. Y. Li, S. Ganta, C. Cheng, R. Craig, R.R. Ganta, and L.C. Freeman FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor Mol. Cell. Endocrinol. 267 2007 26 37
122. 2 + entry and proliferation of prostate cancer epithelial cells Cancer Res. 66 2006 2038 2047
123. 2 +/NFAT-dependent pathways Oncogene 26 2007 7380 7385
124. A. Guilbert, M. Gautier, I. Dhennin-Duthille, N. Haren, H. Sevestre, and H. Ouadid-Ahidouch Evidence that TRPM7 is required for breast cancer cell proliferation Am. J. Physiol. Cell Physiol. 297 2009 C493 C502
125. M. Shabbir, M. Ryten, C. Thompson, D. Mikhailidis, and G. Burnstock Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer BJU Int. 101 2008 352 359
126. M. Shabbir, M. Ryten, C. Thompson, D. Mikhailidis, and G. Burnstock Purinergic receptor-mediated effects of ATP in high-grade bladder cancer BJU Int. 101 2008 106 112
127. 2 + influx Biochem. J. 397 2006 77 87
128. 2 + homeostasis and store-operated channels in prostate cancer cells Cancer Cell 1 2002 169 179
129. 2 + homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells Cell Death Differ. 11 2004 321 330
130. J. Chow, M. Norng, J. Zhang, and J. Chai TRPV6 mediates capsaicin-induced apoptosis in gastric cancer cells - mechanisms behind a possible new "hot" cancer treatment Biochim. Biophys. Acta 1773 2007 565 576
131. 2 +-permeable channel activated by changes in redox status confers susceptibility to cell death Mol. Cell 9 2002 163 173
132. - current and ClC-3 expression in human prostate cancer epithelial cells Cancer Res. 64 2004 4841 4848
133. - current associated with neuroendocrine differentiation of prostate cancer epithelial cells Endocr. Relat. Cancer 12 2005 335 349
134. G. Cheng, Z. Shao, B. Chaudhari, and D.K. Agrawal Involvement of chloride channels in TGF-beta1-induced apoptosis of human bronchial epithelial cells Am. J. Physiol. Lung Cell. Mol. Physiol. 293 2007 L1339 L1347
135. K.H. Weylandt, M. Nebrig, N. Jansen-Rosseck, J.S. Amey, D. Carmena, B. Wiedenmann, C.F. Higgins, and A. Sardini ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment Mol. Cancer Ther. 6 2007 979 986
136. M.Y.A.D. Matte, H. Moses-Soto, and P.A. Kruk Calcium-mediated telomerase activity in ovarian epithelial cells Arch. Biochem. Biophys. 399 2002 239 244
137. L. Munaron Intracellular calcium, endothelial cells and angiogenesis Recent Pat. Anticancer Drug Discov. 1 2006 105 119
138. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat. Rev. Cancer 8 2008 579 591
139. H.W. Cheng, A.F. James, R.R. Foster, J.C. Hancox, and D.O. Bates VEGF activates receptor-operated cation channels in human microvascular endothelial cells Arterioscler. Thromb. Vasc. Biol. 26 2006 1768 1776
140. R. Ge, Y. Tai, Y. Sun, K. Zhou, S. Yang, T. Cheng, Q. Zou, F. Shen, and Y. Wang Critical role of TRPC6 channels in VEGF-mediated angiogenesis Cancer Lett. 283 2009 43 51
141. W.J. Brackenbury, A.M. Chioni, J.K.J. Diss, and M.B.A. Djamgoz The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells Breast Cancer Res. Treat. 101 2007 149 160
142. J.K.J. Diss, D. Stewart, F. Pani, C.S. Foster, M.M. Walker, A. Patel, and M.B.A. Djamgoz A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo Prostate Cancer Prostatic Dis. 8 2005 266 273
143. S.Y. Yang, J.J.L. Zhang, and X.Y. Huang Orai1 and STIM1 are critical for breast tumor cell migration and metastasis Cancer Cell 15 2009 124 134
144. J. Waning, J. Vriens, G. Owsianik, L. Stuwe, S. Mally, A. Fabian, C. Frippiat, B. Nilius, and A. Schwab A novel function of capsaicin-sensitive TRPV1 channels: involvement in cell migration Cell Calcium 42 2007 17 25
145. L.M. Duncan, J. Deeds, J. Hunter, J. Shao, L.M. Holmgren, E.A. Woolf, R.I. Tepper, and A.W. Shyjan Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis Cancer Res. 58 1998 1515 1520
146. N. Kapoor, R. Bartoszewski, Y.J. Qadri, Z. Bebok, J.K. Bubien, C.M. Fuller, and D.J. Benos Knockdown of ASIC1 and epithelial sodium channel subunits inhibits glioblastoma whole cell current and cell migration J. Biol. Chem. 284 2009 24526 24541
147. W.H. Vila-Carriles, G.G. Kovacs, B. Jovov, Z.H. Zhou, A.K. Pahwa, G. Colby, O. Esimai, G.Y. Gillespie, T.B. Mapstone, J.M. Markert, C.M. Fuller, J.K. Bubien, and D.J. Benos Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells J. Biol. Chem. 281 2006 19220 19232
148. N. Innocent, P.D. Livingstone, A. Hone, A. Kimura, T. Young, P. Whiteaker, J.M. McIntosh, and S. Wonnacott Alpha conotoxin arenatus IB[V11l, V16D] is a potent and selective antagonist at rat and human native alpha 7 nicotinic acetylcholine receptors J Pharmacol Exp Ther 327 November 2008 529 537
149. M. Quik, J. Chan, and J. Patrick Alpha-bungarotoxin blocks the nicotinic receptor-mediated increase in cell number in a neuroendocrine cell-line Brain Res. 655 1994 161 167
150. M.B. Djamgoz, and R. Onkal Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic disease Recent Pat. Anticancer Drug Discov. 8 2013 66 84
151. P. Mariot, K. Vanoverberghe, N. Lalevee, M.F. Rossier, and N. Prevarskaya Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells J. Biol. Chem. 277 2002 10824 10833
152. 2 + entry Cancer Res. 60 2000 1002 1008
153. S. Asaga, M. Ueda, H. Jinno, K. Kikuchi, O. Itano, T. Ikeda, and M. Kitajima Identification of a new breast cancer-related gene by restriction landmark genomic scanning Anticancer Res. 26 2006 35 42
154. C.M. Santi, F.S. Cayabyab, K.G. Sutton, J.E. McRory, J. Mezeyova, K.S. Hamming, D. Parker, A. Stea, and T.P. Snutch Differential inhibition of T-type calcium channels by neuroleptics J. Neurosci. 22 2002 396 403
155. J.Y. Lee, S.J. Park, M.J. Lee, H. Rhim, S.H. Seo, and K.S. Kim Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers Bioorg. Med. Chem. Lett. 16 2006 5014 5017
156. W.A. Catterall, E. Perez-Reyes, T.P. Snutch, and J. Striessnig International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels Pharmacol. Rev. 57 2005 411 425
157. + channels support proliferation of colonic carcinoma cells FASEB J. 21 2007 35 44
158. G.C. Koo, J.T. Blake, A. Talento, M. Nguyen, S. Lin, A. Sirotina, K. Shah, K. Mulvany, D. Hora, P. Cunningham, D.L. Wunderler, O.B. McManus, R. Slaughter, R. Bugianesi, J. Felix, M. Garcia, J. Williamson, G. Kaczorowski, N.H. Sigal, M.S. Springer, and W. Feeney Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo J. Immunol. 158 1997 5120 5128
159. + channels of neuroblastoma-cells Cell. Signal. 2 1990 387 393
160. T. Suzuki, and K. Takimoto Selective expression of HERG and Kv2 channels influences proliferation of uterine cancer cells Int. J. Oncol. 25 2004 153 159
161. R.K. Rader, L.E. Kahn, G.D. Anderson, C.L. Martin, K.S. Chinn, and S.A. Gregory T cell activation is regulated by voltage-dependent and calcium-activated potassium channels J. Immunol. 156 1996 1425 1430
162. + channels in breast cancer cells: association with cell cycle progression Am. J. Physiol. Cell Physiol. 287 2004 C125 C134
163. A.K. Weaver, X.J. Liu, and H. Sontheimer Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells J. Neurosci. Res. 78 2004 224 234
164. B.S. Jensen, N. Odum, N.K. Jorgensen, P. Christophersen, and S.P. Olesen Inhibition of T cell proliferation by selective block of Ca(2 +)-activated K(+) channels Proc. Natl. Acad. Sci. U. S. A. 96 1999 10917 10921
165. + channels and the intracellular calcium signal in human melanoma cell proliferation J. Membr. Biol. 151 1996 149 157
166. Y. Tsuji, and D. Dobrev Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update Vasc. Health Risk Manag. 9 2013 165 175
167. G. Bidaux, M. Roudbaraki, C. Merle, A. Crepin, P. Delcourt, C. Slomianny, S. Thebault, J.L. Bonnal, M. Benahmed, F. Cabon, B. Mauroy, and N. Prevarskaya Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement Endocr. Relat. Cancer 12 2005 367 382
168. G. Bidaux, M. Flourakis, S. Thebault, A. Zholos, B. Beck, D. Gkika, M. Roudbaraki, J.L. Bonnal, B. Mauroy, Y. Shuba, R. Skryma, and N. Prevarskaya Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function J. Clin. Invest. 117 2007 1647 1657
169. 2 + transport Nat. Rev. Cancer 7 2007 519 530
170. K. Hill, S. McNulty, and A.D. Randall Inhibition of TRPM2 channels by the antifungal agents clotrimazole and econazole Naunyn Schmiedebergs Arch. Pharmacol. 370 2004 227 237
171. L.J. Yang, D. Ye, W.C. Ye, C.G. Jiao, L.Y. Zhu, J.W. Mao, T.J.C. Jacob, L.W. Wang, and L.X. Chen ClC-3 is a main component of background chloride channels activated under isotonic conditions by autocrine ATP in nasopharyngeal carcinoma cells J. Cell. Physiol. 226 2011 2516 2526